# A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy

Source: https://onco.cc/trials/nct07101627/  
OnCo record `nct07101627` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in lung cancer, run by Shanghai Pulmonary Hospital, Shanghai, China, not yet recruiting.

## Summary

A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy is a phase 2, randomised interventional study registered as NCT07101627 by Shanghai Pulmonary Hospital, Shanghai, China, with a registry enrolment figure of 149 participants, started 2025-08-01 and due to reach its primary completion in 2027-04-30. Interventions recorded: Hetrombopag Tablets. Conditions listed: Lung Cancer. Primary outcome: Incidence of Grade 3 and Higher Thrombocytopenia. Lung eligibility wording from the registry: "Patients with histopathologically confirmed metastatic lung cancer". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07101627
- Phase: 2
- Setting: A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy
- Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
- Enrolled: 149

## Sources

- ClinicalTrials.gov NCT07101627: https://clinicaltrials.gov/study/NCT07101627

## Connected records

- cancers: [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07101627.json